^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZM008

    i
    Other names: ZM008, ZM 008, ZM-008
    Associations

    News

    Trials
    Company:
    Zumutor
    Drug class:
    NK cell stimulant, LLT1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=33, Recruiting, Zumutor Biologics Inc.
    New P1 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ZM008
    over2years
    Abrogation of natural killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers. (ASCO 2022)
    A Phase 1 open label, multicenter dose escalation clinical trial is planned in patients with advanced solid tumors to evaluate the safety and tolerability of ZM008, as monotherapy and in combination with Pembrolizumab. This study for the first time revealed intense staining of LLT1 protein in high Gleason score prostate cancer, demonstrating therapeutic potential of ZM008 in solid cancers not responsive to current I/O checkpoint therapies. Invitro and in vivo experiments have shown human NK cells activation resulting in significant tumor growth reduction. CD56+ NK and CD8+ T cells infiltrations indicate transformation of “Cold tumors” to “Hot tumors”.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1)
    |
    Keytruda (pembrolizumab) • ZM008